Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Wall Street Analysts Predict a 74% Upside in Exelixis (EXEL): Here's What You Should Know
01:55pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
The mean of analysts' price targets for Exelixis (EXEL) points to a 74% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution
01:45pm, Wednesday, 19'th Oct 2022 The Motley Fool
These stocks have low-to-no debt, and analysts see tons of upside.
Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution
09:45am, Wednesday, 19'th Oct 2022
These stocks have low-to-no debt, and analysts see tons of upside.
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
02:21pm, Tuesday, 18'th Oct 2022 Benzinga
Upgrades
According to Jefferies, the prior rating for Target Corp (NYSE:TGT) was changed from Hold to Buy. Target earned $0.39 in the second quarter, compared to $3.64 in the year-ago quarter. The cur
The Smartest Stocks to Buy With $20 Right Now
01:23pm, Friday, 14'th Oct 2022 The Motley Fool
Cheap stocks have the ability to generate enormous, long-term profits for investors.
EXEL vs. TECH: Which Stock Is the Better Value Option?
03:40pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
EXEL vs. TECH: Which Stock Is the Better Value Option?
Should Value Investors Buy Exelixis (EXEL) Stock?
01:40pm, Tuesday, 11'th Oct 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
EXEL vs. TECH: Which Stock Is the Better Value Option?
12:47pm, Tuesday, 11'th Oct 2022
EXEL vs. TECH: Which Stock Is the Better Value Option?
Should Value Investors Buy Exelixis (EXEL) Stock?
11:17am, Tuesday, 11'th Oct 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
These 7 Biotech Stocks Are Set to Boom in 2023
06:15am, Monday, 10'th Oct 2022
Among biotech stocks, there are several established names that have products in markets and deep pipelines. These companies deliver predictable revenue and earnings, and maybe even a dividend for good
Big-Cap S&P Stocks Will Soon Provide Tech-Like Returns, I Explain
04:10am, Monday, 10'th Oct 2022 Seeking Alpha
Learn more about an opportunity to acquire well-known big-cap names in the S&P 500 that, at this point, could provide "tech-like" returns.
Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More
02:28pm, Thursday, 06'th Oct 2022 Zacks Investment Research
Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.
Nasdaq Bear Market: 5 Amazing Growth Stocks You'll Regret Not Buying on the Dip
09:06am, Saturday, 01'st Oct 2022 The Motley Fool
These top-tier companies are begging to be bought following a 34% peak decline in the Nasdaq Composite.
Nasdaq Bear Market: 5 Amazing Growth Stocks You'll Regret Not Buying on the Dip
05:06am, Saturday, 01'st Oct 2022
These top-tier companies are begging to be bought following a 34% peak decline in the Nasdaq Composite.
3 Biotech Stocks to Buy and Hold for the Next 10 Years
12:00pm, Wednesday, 28'th Sep 2022 The Motley Fool
These drugmakers seem to have a knack for innovation.
